Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 526

1.

Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA, Burrows EM, Dees EC, Carey LA.

Ann Surg Oncol. 2011 Oct;18(10):2851-7. doi: 10.1245/s10434-011-1665-8. Epub 2011 Mar 26.

PMID:
21442348
2.

[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].

Zhang HM, Zhang BN, Xuan LX, Zhao P.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Chinese.

PMID:
19950556
3.

Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype.

Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ.

Breast Cancer Res Treat. 2012 Jun;133(3):831-41. doi: 10.1007/s10549-011-1891-6. Epub 2011 Dec 7. Review.

PMID:
22147079
4.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.

Clin Cancer Res. 2007 Apr 15;13(8):2329-34.

5.

Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.

Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA.

Breast Cancer Res. 2012 May 23;14(3):R83.

6.

Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.

Vargo JA, Beriwal S, Ahrendt GM, Soran A, Johnson RR, McGuire K, Bhargava R.

Oncology. 2011;80(5-6):341-9. doi: 10.1159/000330203. Epub 2011 Jul 26.

PMID:
21791944
7.

Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.

Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR.

J Clin Oncol. 2008 May 10;26(14):2373-8. doi: 10.1200/JCO.2007.14.4287. Epub 2008 Apr 14. Erratum in: J Clin Oncol. 2008 Jun;26(18):3110.

PMID:
18413639
8.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
9.

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S.

Breast Cancer Res Treat. 2010 Jan;119(1):119-26. doi: 10.1007/s10549-009-0499-6. Epub 2009 Aug 8.

PMID:
19669409
10.

[Clinical characteristics and prognosis of different subtypes of breast cancer].

Yuan ZY, Wang SS, Zhu MQ, Zheng L, Luo WB, Zhou ZM, Guan ZZ.

Zhonghua Zhong Liu Za Zhi. 2008 Jun;30(6):456-61. Chinese.

PMID:
19024523
11.

Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation.

Panoff JE, Hurley J, Takita C, Reis IM, Zhao W, Sujoy V, Gomez CR, Jorda M, Koniaris L, Wright JL.

Breast Cancer Res Treat. 2011 Aug;128(3):899-906. doi: 10.1007/s10549-011-1495-1. Epub 2011 Apr 8.

PMID:
21475999
12.

Prognosis of Japanese breast cancer based on hormone receptor and HER2 expression determined by immunohistochemical staining.

Nakajima H, Fujiwara I, Mizuta N, Sakaguchi K, Hachimine Y, Konishi E, Yanagisawa A, Magae J.

World J Surg. 2008 Nov;32(11):2477-82. doi: 10.1007/s00268-008-9712-8.

PMID:
18758851
13.

Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.

Breast Cancer Res Treat. 2012 Feb;131(3):827-36. doi: 10.1007/s10549-011-1488-0. Epub 2011 Apr 7.

PMID:
21472434
14.

Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers.

Ibrahim E, Al-Gahmi AM, Zeenelin AA, Zekri JM, Elkhodary TR, Gaballa HE, Fawzy EE, El sayed ME, Alzahrani MS.

Med Oncol. 2009;26(3):372-8. doi: 10.1007/s12032-008-9131-6. Epub 2008 Nov 26.

PMID:
19034706
15.

Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.

Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA.

Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1337-42.

PMID:
15275718
16.

Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.

Swisher SK, Vila J, Tucker SL, Bedrosian I, Shaitelman SF, Litton JK, Smith BD, Caudle AS, Kuerer HM, Mittendorf EA.

Ann Surg Oncol. 2016 Mar;23(3):749-56. doi: 10.1245/s10434-015-4921-5. Epub 2015 Oct 28.

PMID:
26511263
17.

Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation.

Wright JL, Takita C, Reis IM, Zhao W, Saigal K, Wolfson A, Markoe A, Moller M, Hurley J.

Cancer. 2013 Jan 1;119(1):16-25. doi: 10.1002/cncr.27717. Epub 2012 Jun 26.

18.

Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.

Kim HJ, Han W, Yi OV, Shin HC, Ahn SK, Koh BS, Moon HG, You JH, Son BH, Ahn SH, Noh DY.

Breast Cancer Res Treat. 2011 Nov;130(2):499-505. doi: 10.1007/s10549-011-1736-3. Epub 2011 Aug 19.

PMID:
21853352
19.

[Clinical features and prognosis analysis of different breast cancer molecular subtypes].

Yang Q, Chen J, Li HJ, Yu M, Tian CX, Lü Q.

Zhonghua Zhong Liu Za Zhi. 2011 Jan;33(1):42-6. Chinese.

PMID:
21575463
20.

Presenting features of breast cancer differ by molecular subtype.

Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, Morrow M.

Ann Surg Oncol. 2009 Oct;16(10):2705-10. doi: 10.1245/s10434-009-0606-2. Epub 2009 Jul 11.

PMID:
19593632

Supplemental Content

Support Center